ABOLOGIX founded in Geneva, Switzerland

Jan 25, 2018

1 min read

Updated: Feb 28, 2025

Geneva, Switzerland, January 25, 2018 – Abologix, a privately held swiss biotechnology company developing novel immuno-oncology products for the benefit of cancer patients has been founded in Geneva, Switzerland by Dr. Ignacio Faus, Prof. Beat Imhof (University of Geneva) and Prof. Thomas Matthes (Geneva University Hospital ).

Abologix obtains funding from the KICK FUND

Geneva, Switzerland, December 23, 2024 – Abologix has been awarded 100,000 CHF by the KICK FUND to progress its advanced preclinical...

Successful completion of the Innosuisse Innovation Project

Geneva, Switzerland, November 23, 2023 – Abologix successfully completes the Innosuisse-funded program for the initial characterization...

Nomination of product H225 as the lead preclinical candidate

Geneva, Switzerland, December 20, 2022 – Abologix nominates monoclonal antibody H225 (blocker of JAM-C, Junction Adhesion Molecule C) as...

Comments

Couldn’t Load Comments

It looks like there was a technical problem. Try reconnecting or refreshing the page.

Comments

Back to Top